Repligen pancreatic imaging agent succeeds in Phase III study, shares rise
This article was originally published in Scrip
Executive Summary
A week after its shares took a 30% hit following the failure of its investigational biopolar depression drug to outperform a placebo in a midstage study, Repligen got a needed boost when top-line Phase III results showed that the firm's synthetic human secretin RG1068 improved the readability of magnetic resonance imaging (MRI) in identifying structural abnormalities of the pancreatic ducts in patients with acute or chronic pancreatitis (scripintelligence, 8 March 2011).